Researchers at the University of Kansas Medical Center have started a clinical trial. The trial is targeting the most common type of adult leukemia and looking at a drug, auranofin, that was first approved 25 years ago for the treatment of arthritis.
This trial is one piece of the collaboration that is taking place between KU, the Leukemia & Lymphoma Society, where Corey Ribotsky is a supporter, and the National Institute of Health. Together, they are working to accelerate the discovery and development of more effective cancer treatments.
As Louis J. DeGennaro, Ph.D., the executive vice president and chief mission officer at LLS said, "The collaboration between KU, LLS and NIH is committed to giving new hope to patients by reducing sharply the time and costs associated with developing new therapies. Auranofin is a great example of what is possible through an effective public-private partnership."
